KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares Repurchased
Ratios

Halozyme Therapeutics (HALO) Shares Repurchased (2019 - 2025)

Halozyme Therapeutics (HALO) has disclosed Shares Repurchased for 7 consecutive years, with $38.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Shares Repurchased changed N/A to $38.9 million in Q3 2025 year-over-year; TTM through Dec 2025 was $288.9 million, a 15.55% increase, with the full-year FY2025 number at $342.4 million, up 36.95% from a year prior.
  • Shares Repurchased was $38.9 million for Q3 2025 at Halozyme Therapeutics, down from $250.0 million in the prior quarter.
  • In the past five years, Shares Repurchased ranged from a high of $252.3 million in Q4 2023 to a low of $1000.0 in Q4 2022.
  • A 5-year average of $114.6 million and a median of $76.2 million in 2021 define the central range for Shares Repurchased.
  • Peak YoY movement for Shares Repurchased: plummeted 100.0% in 2022, then soared 25229900.0% in 2023.
  • Halozyme Therapeutics' Shares Repurchased stood at $150.0 million in 2021, then tumbled by 100.0% to $1000.0 in 2022, then skyrocketed by 25229900.0% to $252.3 million in 2023, then fell by 0.91% to $250.0 million in 2024, then crashed by 84.45% to $38.9 million in 2025.
  • Per Business Quant, the three most recent readings for HALO's Shares Repurchased are $38.9 million (Q3 2025), $250.0 million (Q4 2024), and $252.3 million (Q4 2023).